Eliminating invasive cervical cancer possible, researchers report

September 28, 2012

Researchers at Moffitt Cancer Center and colleagues at the University of South Florida and The Ohio State University have published a paper in the September issue of Cancer Epidemiology, Biomarkers & Prevention that provides an overview on preventing invasive cervical cancer.

"The good news is that over the past several decades, the incidence of invasive has declined dramatically," said senior author Anna R. Giuliano, Ph.D., director of Moffitt's Center for Infection Research in Cancer and senior member of the Department. "The bad news is that 60 percent of invasive cervical cancers occur in women who are members of underserved racial or ethnic minorities, in women residing in rural areas or living in poverty."

The incidence of invasive cervical cancer has declined 75 percent since the 1940s. According to the authors, rates have decreased from 14.8 per 100,000 women in 1975 to 6.6 per 100,000 in 2008. Credit for the decline is given to the more widespread use of the Pap smear.

The number of current cases of invasive cervical cancer varies by race and ethnicity, geography, and socioeconomic status. For Hispanics, the incidence of invasive cervical cancer is 10.4 per 100,000, higher than any other group. Among blacks 85 and older, the incidence is three times higher than white women in the same age group.

"In looking across the nation, there are geographic and socioeconomic disparities associated with invasive cervical cancer rates," noted lead author Christine M. Pierce Campbell, Ph.D., a postdoctoral fellow within Moffitt's Cancer Epidemiology Department. "Along the U.S.-Mexico border, in the deep South and in Appalachia, rates are higher than in other regions of the nation. Also, many studies have shown that socioeconomic status predicts who gets screened, diagnosed and treated for invasive cervical cancer, regardless of race and ethnicity."

Giuliano, Pierce Campbell and their co-authors also note that federal and local funding of prevention programs, such as the National Breast and Cervical Cancer Early Detection Program, the only nationwide screening program, has helped reduce incidence. Although the National Breast and Cervical Cancer Early Detection Program was implemented to promote screening among high-risk and low-income women, the program has historically served few of the women eligible for the service. The numbers of those taking advantage of the service vary by state, but between 2004 and 2006, only 8.7 percent of women eligible for screening received it, the authors said.

Human papillomavirus (HPV) vaccination, now in two forms, could also reduce incidence, the authors said. GARDASIL, the first HPV vaccine targeting females ages 9 to 26 to prevent invasive cervical cancer, was released in 2006. It was followed by the CERVARIX vaccine, which is targeted to females 10 to 25.

However, HPV vaccine use lags behind other adolescent vaccines, Giuliano said.

"Barriers to HPV vaccination include costs, perceived safety issues, and the perception that vaccination is unnecessary if the woman or child is not sexually active," Pierce Campbell said. "Parental knowledge, attitudes and beliefs influence utilization, as well. Physician recommendation of the HPV vaccine is a key factor to its use, yet many primary care physicians have not been proactive in promoting it, especially to young adolescents in the target age groups."

Because HPV infection in men contributes to HPV infection in women and the subsequent development of invasive cervical cancer, an additional strategy to reduce incidence has been the HPV vaccination of males, the authors said.

"Gender-neutral HPV vaccination would result in maximal disease reduction," they wrote. "Universal HPV vaccination has the potential to reduce the incidence of invasive cervical cancer and its precancerous lesions by 91 percent."

"Invasive cervical cancer can be eliminated in the United States," concluded the authors. "To achieve this goal, we need to adopt a comprehensive national health care program that underscores accessible and equitable health care, one that delivers compassionate care to all. A future without invasive cervical cancer is possible, although we must be innovative and vigilant in our approach to reduce its burden, as well as reduce the disparities in access to screening and overcome the obstacles to vaccination."

Explore further: Lack of clarity about HPV vaccine and the need for cervical cancer screening

Related Stories

Lack of clarity about HPV vaccine and the need for cervical cancer screening

July 7, 2011
The research will be presented today at the Annual Scientific Meeting of the Society of Academic Primary Care, hosted this year by the Academic Unit of Primary Health Care, University of Bristol.

Cervical vaccine also protects against anal cancer risk

August 23, 2011
A vaccine routinely used to shield against cervical cancer caused by the human papillomavirus also reduces women's risk of anal cancer, a study published by the journal The Lancet Oncology on Tuesday says.

Screening for HPV persistence and cervical cancer risk

September 6, 2011
Women over the age of thirty who test positive for HPV (Human Papillomavirus) should be re-tested two years later as part of cervical cancer screening, according to a study published online TK in the Journal of the National ...

Recommended for you

A new weapon against bone metastasis? Team develops antibody to fight cancer

December 11, 2017
In the ongoing battle between cancer and modern medicine, some therapeutic agents, while effective, can bring undesirable or even dangerous side effects. "Chemo saves lives and improves survival, but it could work much better ...

Scientists discover possible master switch for programming cancer immunotherapy

December 11, 2017
During infection or tumor growth, a type of specialized white blood cells called CD8+ T cells rapidly multiply within the spleen and lymph nodes and acquire the ability to kill diseased cells. Some of these killer T cells ...

Liver cancer: Lipid synthesis promotes tumor formation

December 11, 2017
Lipids comprise an optimal energy source and an important cell component. Researchers from the Biozentrum of the University of Basel and from the University of Geneva have now discovered that the protein mTOR stimulates the ...

Use of chemotherapy for early stage breast cancer declines, study says

December 11, 2017
A study of nearly 3,000 women with early stage breast cancer indicates a recent, significant decline in the use of chemotherapy despite the lack of any change in national treatment recommendations or guidelines, according ...

Researchers identify epigenetic orchestrator of pancreatic cancer cells

December 11, 2017
Genentech researchers have identified an enzyme that shifts pancreatic cancer cells to a more aggressive, drug-resistant state by epigenetically modifying the cells' chromatin. The study, which will be published December ...

CAR T, immunotherapy bring new hope for multiple myeloma patients

December 11, 2017
Two investigational immunotherapy approaches, including chimeric antigen receptor (CAR) T cell therapy, have shown encouraging results in the treatment of multiple myeloma patients who had relapsed and were resistant to other ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.